Overview

Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer

Status:
RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This study is a randomized, controlled, open-label, phase II clinical study. This study is designed to evaluate the efficacy and safety of second-line standard treatment sequential TAS-102 and bevacizumab combined with local treatment versus continuous treatment of standard second-line therapy in advanced colorectal cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University